Oct. 22.-25. 2016
Gürzenich, Cologne
P026 (P026) Hodgkin cell-derived extracellular vesicles shape fibroblast activity
P030 (P030) The lymphoid cell specific transcription factor ELF-1 is transcriptionally downregulated and recurrently deleted in classical Hodgkin lymphoma (cHL)
P036 (P036) Tightly regulated FOXO3 expression is critical for the maintenance of cHL
T004 (T004) Analysis of the mutational landscape and dynamics in Hodgkin Lymphoma using NGS
T005 (T005) High expression of programmed cell death receptor 1 (PD-1) in the tumor microenvironment is associated with inferior event free survival in classical Hodgkin Lymphoma
T006 (T006) The AP-1 transcription factor BATF3 regulates MYC expression and is required for tumor cell survival in classical Hodgkin Lymphoma and anaplastic large cell lymphoma
P024 (P024) Inactivation of the putative ubiquitin-E3 ligase PDLIM2 in classical Hodgkin and anaplastic large cell lymphoma
P025 (P025) Determination of the mutational landscape of primary Hodgkin and Reed/Sternberg cells of classical Hodgkin lymphoma
P027 (P027) Prognostic implications of an active, innate or anergic immune response in the Hodgkin lymphoma tumor microenvironment
P028 (P028) Studying the role of oncogenic miR-24-3p in Hodgkin lymphoma
P029 (P029) Characterization of Hodgkin lymphoma clonogenic cells using a new L428 in vivo xenograft model in immunodeficient NOD/SCID-gammac-/- mice and peripheral lymphocytes study in Hodgkin Lymphoma patients
P031 (P031) Mutations in CD58 and MYB in Hodgkin lymphoma
P032 (P032) Re-fusion of small mononucleated Hodgkin cells leads to giant multinucleated Reed-Sternberg cells in Hodgkin lymphoma
P033 (P033) Molecular characterization of Bruton’s Tyrosine Kinase Inhibitor in Hodgkin’s Lymphoma: Cellular and Animal Models
P034 (P034) Functional analysis to elucidate the susceptibility mechanisms of SNPs at the REL, GATA3 and TCF3 loci in classical Hodgkin Lymphoma
P035 (P035) IGH-mediated translocations, recurrent in classic Hodgkin lymphoma, frequently correlate with an aggressive behavior
P037 (P037) In-Vitro and In-Vivo preclinical activity of EDO-S101 in Hodgkin lymphoma
P038 (P038) Hodgkin Reed-Sternberg cells in classical Hodgkin lymphoma are surrounded by T regulatory cells while lymphocyte predominant cells of nodular lymphocyte predominant Hodgkin lymphoma are surrounded by T follicular helper cells
P039 (P039) The incidence of bleomycin induced lung toxicity is increased in Hodgkin lymphoma patients exposed for granulocyte-colony stimulating growth factor
P040 (P040) Correlation between pre-treatment level of soluble PD-L1 and outcome in classical Hodgkin lymphoma included in a prospective study of the Lymphoma Study Association (LYSA)
P041 (P041) Proteasome Inhibitor Therapy (PIT) in Hodgkin Lymphoma (HL): Leveraging Systems Biology Analyses (SBA) for Cell-Specific Transcriptome Alterations and Optimum Combinatorial Therapy
P042 (P042) Telomere maintenance mechanisms and Tumor microenvironment are key factors in the outcome of classic Hodgkin lymphoma
P043 (P043) Phenotypic characterization of circulating lymphocytes in Hodgkin´s lymphoma (HL) with focus on T cells
P044 (P044) SIP-F1: A new gray zone lymphoma cell line?
P045 (P045) CD4 lymphopenia as a prognosis factor in previously untreated Hodgkin lymphoma
P046 (P046) Can plasma chemokines and soluble receptor monitoring predict outcome in classical Hodgkin’s Lymphoma (cHL) patients?
P047 (P047) Expression and prognostic impact of indoleamine 2,3-dioxygenase in Hodgkin’s lymphoma
P048 (P048) Reed-Sternberg Cells on Bone Marrow Cytology: The Very Early Feature on Hemophagocytic Lymphohistiocytosis Associated to Hodgkin Lymphoma
P048B (P048B) A novel PTPN1 splice variant regulates JAK/STAT activity in classical Hodgkin’s lymphoma cells
T010 (T010) Long-term follow-up of contemporary treatment in early-stage favorable Hodgkin Lymphoma (HL): updated analyses of the German Hodgkin Study Group HD7 and HD10 trial
T012 (T012) Results of US intergroup trial of response-adapted chemotherapy or chemotherapy/radiation therapy based on PET for non-bulky stage I and II Hodgkin Lymphoma (HL) (CALGB/Alliance 50604)
P049 (P049) Long-Term Follow-Up of Contemporary Treatment in Early-Stage Unfavorable Hodgkin Lymphoma (HL): Updated Analyses of the German Hodgkin Study Group HD8 and HD11 Trial
P050 (P050) Final Results of a Quality Assurance Program within the German Hodgkin Study Group HD13/14 trial – A report from the radiotherapy reference panel integrating modern guidelines
P051 (P051) Clinical outcome of patients with early stage favorable Hodgkin lymphoma treated with ABVD x 2 cycles followed by PET/CT restaging and 20 Gy of involved-site radiotherapy
P052 (P052) Optimized “butterfly” VMAT reduces mean dose to coronary arteries for early stage HL patients undergoing mediastinal radiotherapy
P053 (P053) Biological evaluation in the treatment planning. Is there a use for patients with Hodgkin’s Lymphoma?
P054 (P054) The effect of deep inspiration breath hold (DIBH) Intensity-Modulated Radiation Therapy (IMRT) on sparing healthy tissues in the treatment of lymphoma involving the mediastinum
P055 (P055) Multicentric Italian Experience in Treatment of Nodular Lymphocyte Predominant Hodgkin lymphoma (NLPHL) in the Rituximab Era
P056 (P056) Construction of a Decision Model to Aid Treatment Choices for Early Stage Hodgkin Lymphoma (ES HL): Bringing Survivorship Forward
P057 (P057) Doses to organs at risk at different modes of 3D-conformal radiotherapy for mediastinal stage II Hodgkin Lymphoma (HL)
P058 (P058) Residual site radiation therapy (RS RT): An opportunity to increase safety of combined modality therapy (CMT) for early stage Hodgkin lymphoma (HL)
T011 (T011) Proton radiotherapy for mediastinal Hodgkin Lymphoma: single institution experience
T001 (T001) BEACOPP escalated followed by radiotherapy of initial bulk or residual disease in advanced-stage Hodgkin Lymphoma: long-term follow-up of the GHSG HD9 and HD12 trials
T002 (T002) Overall survival (OS) impact of BEACOPP versus ABVD in advanced Hodgkin Lymphoma: a pooled analysis of 4 randomized trials
T003 (T003) Long-term follow-up of SWOG S0816: response-adapted therapy of advanced stage Hodgkin Lymphoma using early interim FDG-PET imaging
P001 (P001) Sequential Brentuximab Vedotin (BV) and Adriamycin, Vinblastine, and Dacarbazine (AVD) for Older Patients with Untreated Hodgkin Lymphoma (HL): Findings from a Phase II Window Study
P002 (P002) Preliminary results of a phase II study of brentuximab vedotin using a response adapted design in the first line treatment of patients with Hodgkin lymphoma unsuitable for chemotherapy due to age, frailty or co-morbidity (BREVITY)
P004 (P004) Gray Zone Lymphoma (GZL) with Features Intermediate Between Diffuse Large B-cell Lymphoma (DLBCL) and classical Hodgkin lymphoma (cHL): Diagnostic Experiences and Challenges from a Multicenter Study
P005 (P005) Hodgkin lymphoma in Sweden since 2000: better survival only in elderly women – a Swedish Lymphoma Registry study
P006 (P006) Advanced Hodgkin Lymphoma in the East of England Cancer Network: A 10 year comparative analysis of outcomes for ABVD and escalated BEACOPP treated patients aged 16–59
P007 (P007) Superiority of Modified Progression Free Survival (mPFS) to Evaluate Chemotherapy Effectiveness for Advanced Stage Hodgkin Lymphoma
P008 (P008) Treatment results for Hodgkin Lymphoma in Brazil: first report from the Brazilian Prospective Hodgkin’s Lymphoma Registry
P009 (P009) Dose-Dense/Dose-Intense ABVD (dd-di ABVD) in advanced stage Hodgkin's Lymphoma (HL): A Long-Term Follow Up Study
P010 (P010) THE SWITCH FROM ABVD TO eBEACOPP AS FRONT-LINE THERAPY FOR HIGH-RISK STAGE III-IV CLASSICAL HODGKIN LYMPHOMA (cHL) PATIENTS RESULTS IN AN INVERSION OF EVENT-FREE SURVIVAL (EFS) OF PROGNOSTIC GROUPS
P011 (P011) HALO Study: a phase 1/2 clinical trial of Brentuximab-Vedotin and Bendamustin in elderly patients with previously untreated advanced hodgkin lymphoma. Preliminary data
P012 (P012) Transformation of nodular Hodgkin's lymphoma with lymphocyte predominance to T-cell-rich large B-cell lymphoma
P013 (P013) ABVD AS THE TREATMENT OPTION IN HODGKIN LYMPHOMA WITH LARGE MEDIASTINAL TUMOR
P014 (P014) PERIPHERAL BLOOD EOSINOPHILIA IS A GOOD RISK FACTOR IN POOR PROGNOSIS GROUP: ADVANCED HODGKIN LYMPHOMA WITH LOW ALC/AMC
P015 (P015) Lower socioeconomic status is associated with shorter survival in HL patients – an analysis from the Brazilian Hodgkin Lymphoma Registry
P016 (P016) THE IMPACT OF OUTCOME OF INTERIM PET/CT ON ADVANCED HODGKIN LYMPHOMA TREATED WITH BEACOPP-14
P017 (P017) ADVANCED HODGKIN LYMPHOMA – A RISK STRATIFICATION OF ABVD TREATED FEMALES IN GENERATIVE AGE
P018 (P018) ADVANCED STAGE HODGKIN LYMPHOMA IN MOROCCAN ADULTS: CLINICO-PATHOLOGICAL FEATURES AND THERAPEITIC OUTCOMES
P019 (P019) General population-derived specific survival applied to Hodgkin Lymphoma
P020 (P020) The diagnostics and therapy of Hodgkin lymphoma in pregnancy, the experiences of one center
P021 (P021) Difficulties in distinguishing syncytial variant of nodular sclerosis classical Hodgkin’s lymphoma from diffuse large B-cell lymphoma and complete remission after intensive chemotherapy
P022 (P022) Systemic Hodgkin's Disease with osseal involvement
P023 (P023) Brentuximab Vedotin Alone and in Combination With Dacarbazine or Bendamustine in Patients Aged ≥60 Years With Newly Diagnosed Hodgkin Lymphoma: Interim Results of a Phase 2 Study
T007 (T007) Hodgkin Lymphoma infiltrating T cells: considering various means of tumor evasion
T008 (T008) CCR5 blocking by Maraviroc inhibited recruitment, proliferation and pro-tumor effects of mesenchymal stromal cells and monocytes in 2D and 3D models of Hodgkin Lymphoma microenvironment
T009 (T009) Disturbed antigen presentation in classical Hodgkin Lymphoma: implications for immune checkpoint inhibitor therapy?
T013 (T013) Plasma vesicle-associated miRNAs as therapy response biomarkers in Hodgkin Lymphoma
T014 (T014) Mid-treatment TARC and mid-treatment FDG-PET predict for progression free survival in classical Hodgkin Lymphoma
T015 (T015) A comprehensive analysis of Hodgkin Lymphoma seasonality across various geographic regions
P060 (P060) Evaluation of Serum TARC Levels in Patients at Risk of Progression Following Autologous Stem Cell Transplant for Hodgkin Lymphoma: Results from the AETHERA Trial
P061 (P061) Validation of a clinical/biological prognostic model in a large cohort of elderly patients with a classical Hodgkin lymphoma
P062 (P062) Outcomes and prognostic factors in Hodgkin lymphoma – a single center experience
P063 (P063) Combined prognostic role of TARC protein and PET/CT in patients with Hodgkin lymphoma
P065 (P065) Joint pediatric Hodgkin and Non-Hodgkin lymphoma study group on grey zone lymphoma in children and adolescents
T016 (T016) Whole body functional and anatomical MRI: accuracy in staging and treatment response monitoring in childhood and adolescent Hodgkin’s Lymphoma compared to conventional multimodality imaging (CRUK C23580/A12707)
T017 (T017) Phase III study of response adapted therapy for the treatment of children with newly diagnosed very high risk Hodgkin Lymphoma (Stages IIIB/IVB) (AHOD0831): a report from the Children’s Oncology Group
T018 (T018) Outcomes in adolescents and young adults (AYA) with Hodgkin Lymphoma (HL) treated on US cooperative group protocols: an adult intergroup (E2496) and Children’s Oncology Group (COG AHOD0031) comparative analysis
P066 (P066) Hodgkin lymphoma in children, adolescents and young adults – a comparative study of clinical presentation and treatment outcome
P067 (P067) Pharmacokinetics, Immunogenicity and Safety of Weekly Dosing of Brentuximab Vedotin in Pediatric Patients with Hodgkin Lymphoma
P068 (P068) Approach and Feasibility of Patient-Reported Outcomes (PROs) in a Phase III clinical trial for advanced stage classical Hodgkin Lymphoma (cHL) in children and adolescents
P069 (P069) Prediction of primary treatment response and outcome in pediatric Hodgkin lymphoma using digital gene expression profiling
P070 (P070) Does involved field radiotherapy improve survival rates in pediatric Classic Hodgkin’s Lymphoma?: A retrospective study of 694 children
P071 (P071) CHIPS as a Predictor of Outcome in Radiated vs. Unradiated HL
P073 (P073) Hodgkin lymphoma (HL) in AYA (adolescents and young adults): Results from a single-tertiary-center prospective cohort of 349 patients
P074 (P074) Prognostic value of ‘interim’ positron emission tomography among children with Advanced Hodgkin lymphoma in developing countries; Children Cancer Hospital Egypt experience
P075 (P075) Long-lasting remission in an adolescent with refractory Hodgkin lymphoma after brentuximab vedotin-containing treatment – a case report
P076 (P076) Overview and Survival of Pediatric Advanced stage Hodgkin Lymphoma treated in Developing countries; Children Cancer Hospital Egypt Experience